Pediatric Primary Sclerosing Cholangitis Treatment & Management

  • Author: David A Piccoli, MD; Chief Editor: Carmen Cuffari, MD   more...
 
Updated: Apr 5, 2012
 

Approach Considerations

No pharmacologic therapy has been proven effective for primary sclerosing cholangitis (PSC). Drug therapy is aimed at treating symptoms and managing complications. Orthotopic liver transplantation (OLT) has been proven successful in treating children with primary sclerosing cholangitis. Liver transplantation is the only therapy that can alter the eventual outcome.

Surgical drainage procedures (eg, portoenterostomy, choledochoenterostomy) are insignificant in the management of PSC. These procedures may provide palliation but do not alter the natural history of the disease because of the consistent involvement of the intrahepatic biliary tree. Surgical drainage procedures are associated with an increased risk of cholangitis postoperatively, and subsequent liver transplantation may become technically more difficult.

Dominant strictures of the extrahepatic biliary tree, most often at the bifurcation of the hepatic ducts, are major problems for patients with PSC. Transhepatic or endoscopic balloon dilatation of strictures has been shown to be useful in children with PSC. Short-term stenting of strictures has also demonstrated clinical improvement of symptomatic strictures.

Surgical, endoscopic, and interventional radiologic procedures to relieve symptomatic dominant strictures have been demonstrated to prolong survival time of the native liver in patients with PSC, but none of these interventions have altered the ultimate rate of progression of PSC to end-stage liver disease.

Bacterial cholangitis, which can occur spontaneously, is more common after endoscopic or surgical manipulation of the biliary tree. Episodes of cholangitis require prompt antibiotic therapy.

Next

Pharmacologic Therapy

Pharmacologic treatment of patients with primary sclerosing cholangitis (PSC) should be directed at managing the following[15] :

  • Cirrhosis and portal hypertension
  • Chronic cholestasis with pruritus and malabsorption
  • Ductular complications, such as dominant strictures, cholelithiasis, and ascending bacterial cholangitis
  • Other associated diseases, such as inflammatory bowel disease (IBD) or other autoimmune diseases

Choleretic therapy with ursodeoxycholic acid (UDCA) reportedly improves symptoms and biochemical abnormalities in adult patients with PSC. Some observational and controlled trial data also suggest a reduction in colonic dysplasia rates with UDCA.[16] Children with PSC experience significant improvements in their liver biochemical indices when treated with UDCA; however, the long-term effect of UDCA on the clinical outcome of PSC has not been determined.[17, 18, 19]

Previous
Next

Liver Transplantation

Orthotopic liver transplantation (OLT) has been proven successful in treating children with primary sclerosing cholangitis (PSC). Data from numerous liver transplantation centers demonstrate excellent long-term patient and graft survival for patients with end-stage PSC.[20, 21, 22, 23]

Actuarial patient survival rates after OLT for PSC have been shown to be greater than 90% at 1 year and approximately 90% at 5 years. In one study, although children with PSC had patient- and graft-survival rates equaling those of age-matched children who underwent transplantation for other indications, patients with coexisting inflammatory bowel disease demonstrated poorer outcomes. Overall, posttransplant PSC recurrence was noted in 9.8%, and compared with other graft recipients, PSC patients had higher mean liver enzyme levels 5 years post transplant.[24]

Previous
Next

Diet

As with other cholestatic disorders, provide fat-soluble vitamin supplementation (vitamins A, D, E, K) and nutritional support to ensure adequate growth. If the patient has steatorrhea, medium-chain triglycerides should be added to the diet. If pancreatic enzyme deficiency is present, oral supplementation is necessary, and calcium supplementation for bone disease may also be needed.

Previous
Next

Consultations

Despite progress in early recognition, optimal treatment of patients with primary sclerosing cholangitis remains a challenge and requires a multidisciplinary approach between hepatologists, endoscopists, surgeons, and interventional radiologists. Consultation with a gastroenterologist is necessary, and an endocrinologist may be consulted for management of bone disease.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

David A Piccoli, MD  Chief of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia; Professor, University of Pennsylvania School of Medicine

David A Piccoli, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Chief Editor

Carmen Cuffari, MD  Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine

Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Additional Contributors

Robert Baldassano, MD Director, Center for Pediatric Inflammatory Bowel Disease, Children's Hospital of Philadelphia; Professor, Department of Pediatrics, Division of Gastroenterology and Nutrition, University of Pennsylvania School of Medicine

Robert Baldassano, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References

  1. Roberts EA. Primary sclerosing cholangitis in children. J Gastroenterol Hepatol. Jun 1999;14(6):588-93. [Medline].

  2. Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Semin Immunopathol. May 26 2009;[Medline].

  3. Narayanan Menon KV, Wiesner RH. Etiology and natural history of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg. 1999;6(4):343-51. [Medline].

  4. Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol. Oct 2003;18(10):1118-28. [Medline].

  5. Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. Jul 2003;38(1):210-7. [Medline].

  6. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. Jul 2000;75(7):688-94. [Medline].

  7. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatology. May 1997;25(5):1049-53. [Medline].

  8. The Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Foundation for Medical Education and Research. Available at http://www.mayoclinic.org/gi-rst/mayomodel3.html. Accessed March 30, 2012.

  9. Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology. Jun 1999;29(6):1643-8. [Medline].

  10. Bangarulingam SY, Gossard AA, Petersen BT, Ott BJ, Lindor KD. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol. Apr 2009;104(4):855-60. [Medline].

  11. Angulo P, Pearce DH, Johnson CD, et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol. Oct 2000;33(4):520-7. [Medline].

  12. Revelon G, Rashid A, Kawamoto S, Bluemke DA. Primary sclerosing cholangitis: MR imaging findings with pathologic correlation. AJR Am J Roentgenol. Oct 1999;173(4):1037-42. [Medline].

  13. Rustemovic N, Cukovic-Cavka S, Opacic M, Petrovecki M, Hrstic I, Radic D, et al. Endoscopic ultrasound elastography as a method for screening the patients with suspected primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. Jun 2 2009;[Medline].

  14. Ponsioen CY, Lam K, van Milligen de Wit AW, et al. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol. Sep 1999;94(9):2403-7. [Medline].

  15. Björnsson E. Management of primary sclerosing cholangitis. Minerva Gastroenterol Dietol. Jun 2009;55(2):163-72. [Medline].

  16. Shi J, Li Z, Zeng X, Lin Y, Xie WF. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res. May 7 2009;[Medline].

  17. Gilger MA, Gann ME, Opekun AR, Gleason WA Jr. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr. Aug 2000;31(2):136-41. [Medline].

  18. Pardi DS, Loftus EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerativecolitis and primary sclerosing cholangitis. Gastroenterology. Apr 2003;124(4):889-93. [Medline].

  19. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. Jan 16 2001;134(2):89-95. [Medline]. [Full Text].

  20. Gow PJ, Chapman RW. Liver transplantation for primary sclerosing cholangitis. Liver. Apr 2000;20(2):97-103. [Medline].

  21. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. Nov 1999;30(5):1121-7. [Medline].

  22. Liden H, Norrby J, Friman S, Olausson M. Liver transplantation for primary sclerosing cholangitis--a single- center experience. Transpl Int. 2000;13 Suppl 1:S162-4. [Medline].

  23. Sekido H, Takeda K, Morioka D, et al. Liver transplantation for primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg. 1999;6(4):373-6. [Medline].

  24. Miloh T, Anand R, Yin W, Vos M, Kerkar N, Alonso E. Pediatric liver transplantation for primary sclerosing cholangitis. Liver Transpl. Aug 2011;17(8):925-933. [Medline]. [Full Text].

  25. Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequentialsyndrome. Hepatology. Dec 2002;36(6):1393-9. [Medline].

  26. Angulo P, Larson DR, Therneau TM, et al. Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol. Nov 1999;94(11):3310-3. [Medline].

  27. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitisin a United States community. Gastroenterology. Nov 2003;125(5):1364-9. [Medline].

  28. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. Feb 1998;27(2):311-6. [Medline].

  29. Bharucha AE, Jorgensen R, Lichtman SN, et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. Sep 2000;95(9):2338-42. [Medline].

  30. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. Jan 2000;31(1):7-11. [Medline].

  31. Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. Jul 2005;100(7):1516-22. [Medline].

  32. Harrison PM. Diagnosis of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg. 1999;6(4):356-60. [Medline].

  33. Kita R, Kita-Sasai Y, Hanaoka I, et al. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three casereports). Am J Gastroenterol. Jul 2002;97(7):1849-51. [Medline].

  34. Kugelmas M, Spiegelman P, Osgood MJ, et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitisafter liver transplantation. Liver Transpl. Jul 2003;9(7):727-32. [Medline].

  35. Lee YM, Kaplan MM. Medical treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg. 1999;6(4):361-5. [Medline].

  36. [Guideline] Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. Jul 2006;131(1):278-82. [Medline].

  37. [Guideline] Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. Jun 2005;41(6):1407-32. [Medline].

  38. [Guideline] Murray KF, Carithers RL Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. Jun 2005;41(6):1407-32. [Medline].

  39. Nakanuma Y, Harada K, Katayanagi K, et al. Definition and pathology of primary sclerosing cholangitis. J Hepatobiliary Pancreat Surg. 1999;6(4):333-42. [Medline].

  40. Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. Jun 1999;28(2):491-513. [Medline].

  41. Roozendaal C, de Jong MA, van den Berg AP, et al. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol. May 2000;32(5):734-41. [Medline].

  42. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. Nov 2000;95(11):3195-9. [Medline].

  43. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. Jun 1999;94(6):1643-9. [Medline].

  44. Talwalkar JA, Lindor KD. Primary sclerosing cholangitis. Inflamm Bowel Dis. Jan 2005;11(1):62-72. [Medline].

 
Previous
Next
 
Fibro-obliterative cholangiopathy. Image courtesy of Dr. Kay Washington.
Endoscopic retrograde cholangiopancreatography performed in a patient with abnormal liver function test results shows multiple intrahepatic bile duct strictures and beading.
Double-contrast barium enema (same patient as in the previous image) shows filiform polyps and an ahaustral colon resulting from ulcerative colitis.
Percutaneous transhepatic cholangiogram shows dilatation, stricturing, and beading of the intrahepatic bile ducts. Note the surgical clips from a previous cholecystectomy.
T-tube cholangiogram shows irregularity of the common bile duct, stricturing, beading, and dilatation of the intrahepatic bile ducts. Note a calculus in the termination of the left hepatic duct (arrow).
Magnetic resonance cholangiopancreatography shows a normal-sized common bile duct, but strictures of both the left and right ducts are noted as well as a dilated proximal left hepatic duct.
Technetium-99m iminodiacetic acid scan shows retention of the radionuclide proximal to strictures in the distribution of the left hepatic duct. Note the lack of filling of the gallbladder because of a previous cholecystectomy. Isotope has entered the small bowel.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.